CJC-1295 / Ipamorelin: The Growth Hormone Stack Explained

CJC-1295 and Ipamorelin are almost always discussed together — and for good reason. They work through complementary mechanisms to produce a synergistic increase in growth hormone secretion, and pairing them has become the default approach among people using peptides for GH optimization.

Understanding what each one does individually makes the combination make more sense.

Two Compounds, Two Mechanisms

CJC-1295 is a GHRH analogue — a synthetic version of growth hormone-releasing hormone. GHRH is the signal your hypothalamus sends to the pituitary gland to tell it to release growth hormone. CJC-1295 mimics that signal, amplifying the size of each GH pulse without substantially affecting pulse frequency.

The version most commonly used is CJC-1295 without DAC (Drug Affinity Complex). With DAC, the half-life extends dramatically (days), making dosing less precise. Without DAC, the half-life is roughly 30 minutes, which aligns better with the body's natural pulsatile GH release pattern.

Ipamorelin is a GHRP — a growth hormone-releasing peptide. It works through a different receptor (the ghrelin/GHS receptor) to amplify GH pulses while also providing some blunting of somatostatin (the hormone that suppresses GH release).

Together: CJC-1295 and Ipamorelin both amplify GH pulses, but through two distinct receptor systems, and Ipamorelin adds the somatostatin-blunting effect. Hitting two pathways at once produces a more pronounced — and more physiologically normal — increase in GH output than either compound alone.

Why This Stack and Not Synthetic HGH

Several reasons people choose peptide stacks over exogenous HGH:

1. Physiological pattern. Peptide-stimulated GH release maintains the natural pulsatile pattern — spikes followed by return to baseline. Exogenous HGH produces sustained elevated levels, which may suppress endogenous GH production over time.

2. Pituitary axis preservation. Because these peptides stimulate your own pituitary to release GH rather than replacing it, the axis remains intact. Discontinuation doesn't leave you with suppressed endogenous production.

3. Cost and access. Research peptides are significantly more accessible than pharmaceutical-grade HGH.

4. Self-limiting mechanism. The body's own regulatory feedback (somatostatin, IGF-1 levels) provides a ceiling on GH output, reducing the risk of the overdose effects seen with exogenous HGH.

Dosing Protocol

Standard dosing for the combination:

• CJC-1295 (no DAC): 100–200 mcg per injection
• Ipamorelin: 100–300 mcg per injection
• Combined in the same syringe: yes, they're compatible
• Frequency: 1–3 times daily

The timing matters more than with many other compounds:

• Best timing: fasted state, ideally pre-sleep or pre-workout
• Worst timing: after a carbohydrate-heavy meal; elevated insulin blunts GH release
• Sleep injection: the most commonly used single-dose timing, because the largest natural GH pulse occurs in the first few hours of deep sleep; stacking the peptide dose here amplifies a pulse that's already happening

For people running 2–3x daily, a common schedule is: morning (fasted), pre-workout, and pre-sleep. At minimum 2 hours from the last meal for each injection.

Cycle length: Typically 8–12 weeks, followed by a break.

What People Use This Stack For

• Body composition — lean mass accretion and improved fat oxidation; GH is directly lipolytic
• Recovery — improved sleep quality, faster connective tissue repair, reduced muscle soreness
• Anti-aging — maintaining GH levels that decline with age; often part of longevity-focused protocols
• Performance — in training contexts, the combination of improved recovery and body composition supports progressive overload over time

The effects are not dramatic week-to-week the way anabolic steroids are — this is a months-long protocol with gradual, sustainable improvements.

Expected Effects and Timeline

Weeks 1–3: Improved sleep quality is usually the first effect people notice — deeper sleep, more vivid dreams, waking more rested. This is partly GH-mediated and partly ipamorelin's mild sedative quality.

Weeks 4–8: Improved recovery, some change in body composition (fat loss and/or lean mass increase, depending on nutrition), improved skin quality.

Weeks 8–12: Full protocol effects visible; most people assess whether to continue, cycle off, or adjust dose at this point.

IGF-1 blood testing at baseline and at 8–12 weeks is the most objective way to measure whether the protocol is producing meaningful GH stimulation.

Side Effects

Ipamorelin is specifically selected among GHRPs because it's highly selective — it doesn't significantly raise cortisol or prolactin the way other GHRPs (like GHRP-6 or GHRP-2) do. GHRP-6 in particular is known for stimulating ghrelin strongly, driving significant hunger; ipamorelin is much cleaner in this regard.

Common minor effects:

• Water retention — especially early in the protocol; usually resolves
• Tingling or numbness in extremities — carpal tunnel-like symptoms, particularly at higher doses; a known GH effect
• Vivid dreams — generally reported positively
• Mild fatigue — early in some protocols, particularly post-injection

Managing a 1–3x Daily Protocol

This is one of the more logistically demanding peptide protocols. Three subcutaneous injections daily, each with timing constraints (fasted, away from meals) and a fixed schedule, creates real complexity.

What to track:

• Injection times — with meal timestamps; the fasted window needs documentation to be managed
• Dose per injection — especially if dose varies between morning/workout/sleep injections
• Injection sites — rotating across three or more injections per day
• Sleep quality — the pre-sleep injection's primary near-term effect; a nightly rating tells you if the protocol is working early
• Recovery subjective markers — DOMS severity, how you feel post-training
• IGF-1 labs — baseline and at 8–12 weeks; the objective anchor for everything else
• Body composition — weight and ideally body fat measurement at regular intervals

Three daily injections across a 12-week cycle is 252 injection events. Tracking them without infrastructure means relying on memory for a protocol where timing precision is a core variable. Milos is a purpose-built iOS peptide tracker designed for exactly this — timestamped injection logging, site rotation, meal window notes, sleep quality ratings, and a full protocol history across the cycle.

Bottom Line

CJC-1295 / Ipamorelin is the standard peptide approach to growth hormone optimization for good reason — it's well-characterized, produces meaningful results across body composition, recovery, and sleep quality, and preserves the physiological GH axis rather than replacing it.

The protocol demands are real: timing precision, multiple daily injections, and a multi-month commitment. Done properly, with structured tracking and periodic bloodwork, it's one of the cleaner interventions available in this category.